FIGURE 1.

NCT03420768 study design. Eligible patients were randomized 1:1:2 to receive placebo or BMS‐986263 (45 mg or 90 mg) i.v. QW for 12 weeks. ^aLiver biopsies were performed within 8 weeks prior to or during the screening period